Although early investigation has shown promise in the effect of MEK inhibitors in the treatment of glioblastoma with significant antiproliferative effects, the issue of compensatory resistance mechanisms and rebound aggressiveness among MEK-inhibited cell lines remains. This evidence concerns the gene MAP2K7 and glioblastoma.